A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors

BACKGROUND: Treatment with tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML) is effective but needs to continue for several years, possibly indefinitely. Although generally safe, TKI may have hitherto poorly recognized effects in the quality of life (QoL) of such pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zulbaran‐Rojas, Alejandro, Lin, Huei‐Kan, Shi, Qiuling, Williams, Loretta A., George, Binsah, Garcia‐Manero, Guillermo, Jabbour, Elias, O’Brien, Susan, Ravandi, Farhad, Wierda, William, Estrov, Zeev, Borthakur, Gautam, Kadia, Tapan, Cleeland, Charles, Cortes, Jorge E., Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246941/
https://www.ncbi.nlm.nih.gov/pubmed/30318751
http://dx.doi.org/10.1002/cam4.1808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246941/
https://www.ncbi.nlm.nih.gov/pubmed/30318751
http://dx.doi.org/10.1002/cam4.1808

Ejemplares similares